Global Pulmonary Fibrosis Drug Market

Pulmonary Fibrosis Drug Comprehensive Study by Drug (Pirfenidone, Nintedanib, Others), Form (Pills, Solutions, Tablets, Others), Distribution (Hospital Dispensaries, Retail Pharmacies, Third Party Online Sales) Players and Region - Global Market Outlook to 2027

Pulmonary Fibrosis Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Pulmonary Fibrosis Drug
Idiopathic pulmonary fibrosis (IPF) is a long-term lung condition that progressively worsens. The lungs stiffen as a result of scarring on the walls of the alveolar sacs (interstitium), which limits the lungs' capacity to absorb oxygen. This causes shortness of breath, which becomes worse as you exercise less and less. While there is no cure for IPF, medicines can assist with symptoms and reduce the disease's development. Because IPF patients' lung function and symptoms usually worsen with time, treatment is critical. Corticosteroids, azathioprine, and cyclophosphamide are the most often prescribed anti-inflammatory drugs. Colchicine, pirfenidone, and interferon-gamma (IFN-gamma) are all antifibrotic drugs that are becoming more popular.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Pulmonary Fibrosis Drug market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Boehringer Ingelheim (Germany), MediciNova, Inc. (United States), Cipla Limited (India), Biogen (United States), F. Hoffmann-La Roche (Switzerland), Galapagos NV (Belgium), FibroGen, Inc. (United States), Merck KGaA (Germany), Bristol-Myers Squibb Company (United States) and Prometic Life Sciences Inc. (Canada) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Pulmonary Fibrosis Drug market by and Region.

On the basis of geography, the market of Pulmonary Fibrosis Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug, the sub-segment i.e. Pirfenidone will boost the Pulmonary Fibrosis Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Form, the sub-segment i.e. Pills will boost the Pulmonary Fibrosis Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution, the sub-segment i.e. Hospital Dispensaries will boost the Pulmonary Fibrosis Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies

On 14th October, 2020 - Glenmark Pharma Launched Pulmonary Fibrosis Treatment Drug in India. The New Offering is the Generic Version of Nintedanib (NINDANIB), Followed by Two Clinical Trials to Study the Efficacy and Safety of Nintedanib as a treatment of SARS-COV2 Induced Pulmonary Fibrosis in COVID-19 patients.


Market Drivers
  • Prevalence of Pulmonary Fibrosis Cases
  • Rising Geriatric Population

Opportunities
  • Increasing Demand Across Emerging Regions

Restraints
  • Side Effect and Adverse Reactions
  • Lack of Trained Professionals

Challenges
  • Fierce Competitive Pressure
  • High Initial Investment


Key Target Audience
Pulmonary Fibrosis Drug Manufactures, New Entrants and Investors, Pulmonary Fibrosis Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Drug
  • Pirfenidone
  • Nintedanib
  • Others

By Form
  • Pills
  • Solutions
  • Tablets
  • Others

By Distribution
  • Hospital Dispensaries
  • Retail Pharmacies
  • Third Party Online Sales

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Pulmonary Fibrosis Cases
      • 3.2.2. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive Pressure
      • 3.3.2. High Initial Investment
    • 3.4. Market Trends
      • 3.4.1. High Investment in Pharma R&D
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pulmonary Fibrosis Drug, by Drug, Form, Distribution and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Pulmonary Fibrosis Drug (Value)
      • 5.2.1. Global Pulmonary Fibrosis Drug by: Drug (Value)
        • 5.2.1.1. Pirfenidone
        • 5.2.1.2. Nintedanib
        • 5.2.1.3. Others
      • 5.2.2. Global Pulmonary Fibrosis Drug by: Form (Value)
        • 5.2.2.1. Pills
        • 5.2.2.2. Solutions
        • 5.2.2.3. Tablets
        • 5.2.2.4. Others
      • 5.2.3. Global Pulmonary Fibrosis Drug by: Distribution (Value)
        • 5.2.3.1. Hospital Dispensaries
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Third Party Online Sales
      • 5.2.4. Global Pulmonary Fibrosis Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Pulmonary Fibrosis Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boehringer Ingelheim (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. MediciNova, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cipla Limited (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biogen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Galapagos NV (Belgium)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. FibroGen, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck KGaA (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bristol-Myers Squibb Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Prometic Life Sciences Inc. (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pulmonary Fibrosis Drug Sale, by Drug, Form, Distribution and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Pulmonary Fibrosis Drug (Value)
      • 7.2.1. Global Pulmonary Fibrosis Drug by: Drug (Value)
        • 7.2.1.1. Pirfenidone
        • 7.2.1.2. Nintedanib
        • 7.2.1.3. Others
      • 7.2.2. Global Pulmonary Fibrosis Drug by: Form (Value)
        • 7.2.2.1. Pills
        • 7.2.2.2. Solutions
        • 7.2.2.3. Tablets
        • 7.2.2.4. Others
      • 7.2.3. Global Pulmonary Fibrosis Drug by: Distribution (Value)
        • 7.2.3.1. Hospital Dispensaries
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Third Party Online Sales
      • 7.2.4. Global Pulmonary Fibrosis Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pulmonary Fibrosis Drug: by Drug(USD Million)
  • Table 2. Pulmonary Fibrosis Drug Pirfenidone , by Region USD Million (2016-2021)
  • Table 3. Pulmonary Fibrosis Drug Nintedanib , by Region USD Million (2016-2021)
  • Table 4. Pulmonary Fibrosis Drug Others , by Region USD Million (2016-2021)
  • Table 5. Pulmonary Fibrosis Drug: by Form(USD Million)
  • Table 6. Pulmonary Fibrosis Drug Pills , by Region USD Million (2016-2021)
  • Table 7. Pulmonary Fibrosis Drug Solutions , by Region USD Million (2016-2021)
  • Table 8. Pulmonary Fibrosis Drug Tablets , by Region USD Million (2016-2021)
  • Table 9. Pulmonary Fibrosis Drug Others , by Region USD Million (2016-2021)
  • Table 10. Pulmonary Fibrosis Drug: by Distribution(USD Million)
  • Table 11. Pulmonary Fibrosis Drug Hospital Dispensaries , by Region USD Million (2016-2021)
  • Table 12. Pulmonary Fibrosis Drug Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 13. Pulmonary Fibrosis Drug Third Party Online Sales , by Region USD Million (2016-2021)
  • Table 14. South America Pulmonary Fibrosis Drug, by Country USD Million (2016-2021)
  • Table 15. South America Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 16. South America Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 17. South America Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 18. Brazil Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 19. Brazil Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 20. Brazil Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 21. Argentina Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 22. Argentina Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 23. Argentina Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 24. Rest of South America Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 25. Rest of South America Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 26. Rest of South America Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 27. Asia Pacific Pulmonary Fibrosis Drug, by Country USD Million (2016-2021)
  • Table 28. Asia Pacific Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 29. Asia Pacific Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 30. Asia Pacific Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 31. China Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 32. China Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 33. China Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 34. Japan Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 35. Japan Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 36. Japan Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 37. India Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 38. India Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 39. India Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 40. South Korea Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 41. South Korea Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 42. South Korea Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 43. Taiwan Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 44. Taiwan Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 45. Taiwan Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 46. Australia Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 47. Australia Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 48. Australia Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 52. Europe Pulmonary Fibrosis Drug, by Country USD Million (2016-2021)
  • Table 53. Europe Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 54. Europe Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 55. Europe Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 56. Germany Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 57. Germany Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 58. Germany Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 59. France Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 60. France Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 61. France Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 62. Italy Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 63. Italy Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 64. Italy Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 65. United Kingdom Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 66. United Kingdom Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 67. United Kingdom Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 68. Netherlands Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 69. Netherlands Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 70. Netherlands Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 71. Rest of Europe Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 72. Rest of Europe Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 73. Rest of Europe Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 74. MEA Pulmonary Fibrosis Drug, by Country USD Million (2016-2021)
  • Table 75. MEA Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 76. MEA Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 77. MEA Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 78. Middle East Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 79. Middle East Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 80. Middle East Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 81. Africa Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 82. Africa Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 83. Africa Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 84. North America Pulmonary Fibrosis Drug, by Country USD Million (2016-2021)
  • Table 85. North America Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 86. North America Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 87. North America Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 88. United States Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 89. United States Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 90. United States Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 91. Canada Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 92. Canada Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 93. Canada Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 94. Mexico Pulmonary Fibrosis Drug, by Drug USD Million (2016-2021)
  • Table 95. Mexico Pulmonary Fibrosis Drug, by Form USD Million (2016-2021)
  • Table 96. Mexico Pulmonary Fibrosis Drug, by Distribution USD Million (2016-2021)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Pulmonary Fibrosis Drug: by Drug(USD Million)
  • Table 108. Pulmonary Fibrosis Drug Pirfenidone , by Region USD Million (2022-2027)
  • Table 109. Pulmonary Fibrosis Drug Nintedanib , by Region USD Million (2022-2027)
  • Table 110. Pulmonary Fibrosis Drug Others , by Region USD Million (2022-2027)
  • Table 111. Pulmonary Fibrosis Drug: by Form(USD Million)
  • Table 112. Pulmonary Fibrosis Drug Pills , by Region USD Million (2022-2027)
  • Table 113. Pulmonary Fibrosis Drug Solutions , by Region USD Million (2022-2027)
  • Table 114. Pulmonary Fibrosis Drug Tablets , by Region USD Million (2022-2027)
  • Table 115. Pulmonary Fibrosis Drug Others , by Region USD Million (2022-2027)
  • Table 116. Pulmonary Fibrosis Drug: by Distribution(USD Million)
  • Table 117. Pulmonary Fibrosis Drug Hospital Dispensaries , by Region USD Million (2022-2027)
  • Table 118. Pulmonary Fibrosis Drug Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 119. Pulmonary Fibrosis Drug Third Party Online Sales , by Region USD Million (2022-2027)
  • Table 120. South America Pulmonary Fibrosis Drug, by Country USD Million (2022-2027)
  • Table 121. South America Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 122. South America Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 123. South America Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 124. Brazil Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 125. Brazil Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 126. Brazil Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 127. Argentina Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 128. Argentina Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 129. Argentina Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 130. Rest of South America Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 131. Rest of South America Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 132. Rest of South America Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 133. Asia Pacific Pulmonary Fibrosis Drug, by Country USD Million (2022-2027)
  • Table 134. Asia Pacific Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 135. Asia Pacific Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 136. Asia Pacific Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 137. China Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 138. China Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 139. China Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 140. Japan Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 141. Japan Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 142. Japan Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 143. India Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 144. India Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 145. India Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 146. South Korea Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 147. South Korea Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 148. South Korea Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 149. Taiwan Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 150. Taiwan Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 151. Taiwan Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 152. Australia Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 153. Australia Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 154. Australia Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 155. Rest of Asia-Pacific Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 156. Rest of Asia-Pacific Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 157. Rest of Asia-Pacific Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 158. Europe Pulmonary Fibrosis Drug, by Country USD Million (2022-2027)
  • Table 159. Europe Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 160. Europe Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 161. Europe Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 162. Germany Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 163. Germany Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 164. Germany Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 165. France Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 166. France Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 167. France Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 168. Italy Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 169. Italy Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 170. Italy Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 171. United Kingdom Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 172. United Kingdom Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 173. United Kingdom Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 174. Netherlands Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 175. Netherlands Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 176. Netherlands Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 177. Rest of Europe Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 178. Rest of Europe Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 179. Rest of Europe Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 180. MEA Pulmonary Fibrosis Drug, by Country USD Million (2022-2027)
  • Table 181. MEA Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 182. MEA Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 183. MEA Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 184. Middle East Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 185. Middle East Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 186. Middle East Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 187. Africa Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 188. Africa Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 189. Africa Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 190. North America Pulmonary Fibrosis Drug, by Country USD Million (2022-2027)
  • Table 191. North America Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 192. North America Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 193. North America Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 194. United States Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 195. United States Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 196. United States Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 197. Canada Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 198. Canada Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 199. Canada Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 200. Mexico Pulmonary Fibrosis Drug, by Drug USD Million (2022-2027)
  • Table 201. Mexico Pulmonary Fibrosis Drug, by Form USD Million (2022-2027)
  • Table 202. Mexico Pulmonary Fibrosis Drug, by Distribution USD Million (2022-2027)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pulmonary Fibrosis Drug: by Drug USD Million (2016-2021)
  • Figure 5. Global Pulmonary Fibrosis Drug: by Form USD Million (2016-2021)
  • Figure 6. Global Pulmonary Fibrosis Drug: by Distribution USD Million (2016-2021)
  • Figure 7. South America Pulmonary Fibrosis Drug Share (%), by Country
  • Figure 8. Asia Pacific Pulmonary Fibrosis Drug Share (%), by Country
  • Figure 9. Europe Pulmonary Fibrosis Drug Share (%), by Country
  • Figure 10. MEA Pulmonary Fibrosis Drug Share (%), by Country
  • Figure 11. North America Pulmonary Fibrosis Drug Share (%), by Country
  • Figure 12. Global Pulmonary Fibrosis Drug share by Players 2021 (%)
  • Figure 13. Global Pulmonary Fibrosis Drug share by Players (Top 3) 2021(%)
  • Figure 14. Global Pulmonary Fibrosis Drug share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Boehringer Ingelheim (Germany) Revenue: by Geography 2021
  • Figure 18. MediciNova, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. MediciNova, Inc. (United States) Revenue: by Geography 2021
  • Figure 20. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 21. Cipla Limited (India) Revenue: by Geography 2021
  • Figure 22. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 23. Biogen (United States) Revenue: by Geography 2021
  • Figure 24. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2021
  • Figure 26. Galapagos NV (Belgium) Revenue, Net Income and Gross profit
  • Figure 27. Galapagos NV (Belgium) Revenue: by Geography 2021
  • Figure 28. FibroGen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. FibroGen, Inc. (United States) Revenue: by Geography 2021
  • Figure 30. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Merck KGaA (Germany) Revenue: by Geography 2021
  • Figure 32. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2021
  • Figure 34. Prometic Life Sciences Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 35. Prometic Life Sciences Inc. (Canada) Revenue: by Geography 2021
  • Figure 36. Global Pulmonary Fibrosis Drug: by Drug USD Million (2022-2027)
  • Figure 37. Global Pulmonary Fibrosis Drug: by Form USD Million (2022-2027)
  • Figure 38. Global Pulmonary Fibrosis Drug: by Distribution USD Million (2022-2027)
  • Figure 39. South America Pulmonary Fibrosis Drug Share (%), by Country
  • Figure 40. Asia Pacific Pulmonary Fibrosis Drug Share (%), by Country
  • Figure 41. Europe Pulmonary Fibrosis Drug Share (%), by Country
  • Figure 42. MEA Pulmonary Fibrosis Drug Share (%), by Country
  • Figure 43. North America Pulmonary Fibrosis Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Boehringer Ingelheim (Germany)
  • MediciNova, Inc. (United States)
  • Cipla Limited (India)
  • Biogen (United States)
  • F. Hoffmann-La Roche (Switzerland)
  • Galapagos NV (Belgium)
  • FibroGen, Inc. (United States)
  • Merck KGaA (Germany)
  • Bristol-Myers Squibb Company (United States)
  • Prometic Life Sciences Inc. (Canada)
Select User Access Type

Key Highlights of Report


Jun 2022 154 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pulmonary Fibrosis Drug Market Quantitative research analysis
Global Pulmonary Fibrosis Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Boehringer Ingelheim (Germany), MediciNova, Inc. (United States), Cipla Limited (India), Biogen (United States), F. Hoffmann-La Roche (Switzerland), Galapagos NV (Belgium), FibroGen, Inc. (United States), Merck KGaA (Germany), Bristol-Myers Squibb Company (United States) and Prometic Life Sciences Inc. (Canada) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"High Investment in Pharma R&D" is seen as one of major influencing trends for Pulmonary Fibrosis Drug Market during projected period 2021-2027.

Know More About Global Pulmonary Fibrosis Drug Market Report?

Have a Query? Click Here

Other Related Reports

Anti-CD19 Comprehensive Study by Type (Antibody Drug Conjugates, Chimeric Antigen Receptor (CAR) T-Cell Therapy (CAR-T Therapies), Engineered Antibodies, Bispecific Antibody (BsAb)), Application (Hos...
$ 3350
Tool Enzyme Comprehensive Study by Application (Nucleic Acid Amplification Testing, Protein and Small Molecule Detection, Other), Category (DNA Restriction Endonuclease, Ligase, Polymerase, Nuclease,...
$ 3450
Ligand Binding Assay Comprehensive Study by Type (Antigen Discovery Inc, Radioactive, Non-Radioactive), Application (Biomedical Research, Drug Discovery, Others) Players and Region - Global Market Ou...
$ 3500
Enzyme Indicators Comprehensive Study by Application (Bio-decontamination, Drug Development, Pesticide synthesis), End Use (Biopharma Industries, Ambulatory Surgical Centers, Hospitals And Clinics, D...
$ 3350
Whole Genome Amplification Comprehensive Study by Type (Single Cell WGA Kit, Complete WGA Kit, WGA Reamplification Kit, WGA and Chip DNA Kit, Others), Application (Drug Discovery and Development, Dis...
$ 3650
Enzyme Markers Comprehensive Study by Type (Industrial Enzymes, Specialty Enzymes), Application (Food and Beverages, Meat processing products, Dairy products, Beverages, Bakery & confectionary, Nutra...
$ 3450